Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease
Alimentary Pharmacology & Therapeutics ( IF 8.171 ) Pub Date : 2021-11-09 , DOI: 10.1111/apt.16656
Shiva T. Radhakrishnan, James L. Alexander, Benjamin H. Mullish, Kate I. Gallagher, Nick Powell, Lucy C. Hicks, Ailsa L. Hart, Jia V. Li, Julian R. Marchesi, Horace R. T. Williams
The gut microbiota has been implicated in the pathogenesis of inflammatory bowel disease (IBD), with Faecalibacterium prausnitizii associated with protection, and certain genera (including Shigella and Escherichia) associated with adverse features. The variability of patient response to medical therapies in IBD is incompletely understood. Given the recognised contribution of the microbiota to treatment efficacy in other conditions, there may be interplay between the gut microbiota, IBD medical therapy and IBD phenotype.
腸道微生物群與炎症性腸病藥物治療之間的關聯
腸道微生物群 與炎症性腸病 (IBD) 的發病機制有關，普拉梭菌與保護相關，某些屬（包括志賀氏菌和埃希氏菌）與不良特徵相關。IBD 患者對藥物治療反應的變異性尚不完全清楚。鑒於肠道微生物群 ， 在其他情況下對治療效果的公認貢獻，腸道微生物群、IBD 藥物治療和 IBD 表型之間可能存在相互作用。
